Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8498188 | 0.80 | ALDH1A1 (0.47) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL1165632 | 0.79 | MAPT (0.44) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL812586 | 0.74 | MAPT (0.52) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL20503175 | 0.69 | ALDH1A1 (0.43) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL62940 | 0.68 | MAPT (0.46) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| Benzene SCHEMBL27623239 | 0.68 | MAPT (0.46) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL6709727 | 0.68 | GSK3A (0.44) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL1163597 | 0.67 | MGLL (0.50) | MAPTHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1041075 | 0.67 | MAPT (0.41) | MAPTHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL30872008 | 0.66 | CASP3 (0.48) | MAPTHSD17B10ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551182-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2019-10-16 | — | — | EP | claimed |
| WO-2018106108-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | KEPPEL HESSELING, Jan Marius (NL) | 2018-06-14 | — | — | WO | claimed |
| US-20130005786-A1 | THERAPEUTIC INVENTION | KAPOOR RAJU (GB) | 2013-01-03 | — | — | US | claimed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | disclosed |
| EP-3551166-B1 | TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2024-08-21 | — | — | EP | disclosed |
| US-11285099-B2 | Topical phenytoin for use in the treatment of peripheral neuropathic pain | TOPICAL INNOVATIONS B.V. (NL) | 2022-03-29 | — | — | US | disclosed |
| US-11147799-B2 | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain | Keppel Hesselink, Jan Marius (NL) | 2021-10-19 | — | — | US | disclosed |
| US-20200276106-A1 | TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2020-09-03 | — | — | US | disclosed |
| US-20200069649-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -) ANALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2020-03-05 | — | — | US | disclosed |
| EP-3551182-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2019-10-16 | — | — | EP | disclosed |
| EP-3551166-A1 | TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018106107-A1 | TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | KOPSKY DAVID JOS (NL) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106108-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | KEPPEL HESSELING, Jan Marius (NL) | 2018-06-14 | — | — | WO | disclosed |
| US-20130005786-A1 | THERAPEUTIC INVENTION | KAPOOR RAJU (GB) | 2013-01-03 | — | — | US | disclosed |
| US-6737547-B1 | Compositions containing and methods of using N-acyl-1H-aminoindenes | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-05-18 | — | — | US | disclosed |
| WO-2000038673-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING N-ACYL-1H-AMINOINDENES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2000-07-06 | — | — | WO | disclosed |
| US-5763191-A | BINDING MATRIX | BOEHRINGER MANNHEIM GMBH (DE) | 1998-06-09 | — | — | US | disclosed |
| US-3932182-A | An organic photoconductive composition comprising an organic photoconductive compound and a sensitizing compound having an active methylene group | MITSUBISHI PAPER MILLS, LTD. (JA) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005786-A1 | THERAPEUTIC INVENTION | AQP4, PMP22, NHERF1 | MAPT 1803/4885HSD17B10 1855/4885ALDH1A1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.